AG
BLPH

Advisor Group’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Advisor Group’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-18
Closed -$1K – 5149
2017
Q4 		$1K Buy
+18
New +$472 ﹤0.01% 4901

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Advisor Group's BLPH Position: Q1 2018 in Review

Advisor Group sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q1 2018, closing a stake of 18 shares — an estimated $1K sold.

Advisor Group first reported a position in BLPH in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 31 funds tracked by Wall St. Rank hold BLPH as of Q1 2018.

  • Advisor Group reported no remaining Bellerophon Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Advisor Group sold 18 Bellerophon Therapeutics, Inc. shares in Q1 2018, an estimated $1K.
  • Advisor Group first reported a position in Bellerophon Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Advisor Group's Bellerophon Therapeutics, Inc. position peaked at $1K in Q4 2017.
  • 31 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q1 2018.

Based on Advisor Group's 13F filing for Q1 2018, filed 15 May 2018.